Patients with diabetes receiving treatment for CRC may experience more neuropathic symptoms
the ONA take:
Patients with colorectal cancer who also have diabetes experienced more neuropathic symptoms, regardless of cancer treatment, according to a recent study published in the Journal of Cancer Survivorship.
Researchers found that patients with colorectal cancer and diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands, tingling toes or feet, numbness in toes or feet, and erectile dysfunction among men, than patients without diabetes.
The study demonstrated no differences in cancer treatment between patients with colorectal cancer and diabetes compared with those without diabetes.
The authors conclude that diabetes rather than chemotherapy results in more neuropathic symptoms among patients with cancer and diabetes compared with those without diabetes.
The findings ultimately suggest that up to 39% of cancer survivors might expect mostly mild, neuropathic symptoms, with more symptoms occurring in patients with diabetes.
Neuropathic symptoms are typically associated with the chemotherapy agent oxaliplatin, which is often used in combination with fluorouracil, leucovorin, and sometimes irinotecan in the treatment of colorectal cancer.
Patients with colorectal cancer who also have diabetes experienced more neuropathic symptoms, regardless of cancer treatment.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|